Screener / SEC EDGAR /CIK 0001232524 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Jazz Pharmaceuticals plc JAZZ

Compare with peers Embed
FY2025 at a glance

Sales up 4.9%, free cash flow down to $1.3B

XBRL, from each 10-K
RevenueStatements
$4.3B from $4.1B in FY2024
FY2016FY2025
Net incomeStatements
-$356.1M from $560.1M in FY2024
FY2016FY2025
Free cash flowStatements
$1.3B from $1.4B in FY2024
FY2016FY2025
EPS (diluted)Statements
$-5.84 from $8.65 in FY2024
FY2016FY2025
Operating marginStatements
-10.1% from 17.6% in FY2024
FY2016FY2025
Total debtStatements
$5.4B from $6.1B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
3.38
Sales (ttm)
4.7B
Net income (ttm)
206.0M
Sales growth
+4.9%
EPS growth
to a loss
Sales Q/Q
+10.4%
Free cash flow
1.6B
Gross margin
-
Oper. margin
9.0%
Net margin
4.4%
FCF margin
34.4%
ROE
4.9%
ROA
1.7%
R&D / sales
18.3%
Dividend
-
Debt/Eq
1.33
Curr. ratio
1.82
Cash
2.0B
Op. cash flow (ttm)
1.7B
EBITDA
-388.6M
EBITDA margin
-9.1%
Net debt
3.5B
Quick ratio
1.66
Interest cover
-1.73
FCF after stock pay
1.0B
Debt / FCF (years)
4.29
Goodwill / assets
15.7%
Oper. margin low 5y
-10.1%
Stock pay / sales
6.8%
Shares out.
64.2M
Shares Y/Y
-7.6%
Book / share
65.30
Cash / share
31.73
Sales / share
73.50
Asset turnover
0.39
Days sales out.
71
Sales 3Y CAGR
+5.3%
Sales 5Y CAGR
+12.5%
Employees
2,890
Sales / employee
1.6M

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 4.3B +12.4% a year Net income -356.1M
FY2016 revenue 1.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-19-000013 FY2016 net income 396.8M · NetIncomeLoss, 0001232524-19-000013 1.5B FY2016 FY2017 revenue 1.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-20-000016 FY2017 net income 487.8M · NetIncomeLoss, 0001232524-20-000016 1.6B FY2017 FY2018 revenue 1.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-21-000016 FY2018 net income 447.1M · NetIncomeLoss, 0001232524-21-000016 1.9B FY2018 FY2019 revenue 2.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-22-000012 FY2019 net income 523.4M · NetIncomeLoss, 0001232524-22-000012 2.2B FY2019 FY2020 revenue 2.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-23-000015 FY2020 net income 238.6M · NetIncomeLoss, 0001232524-23-000015 2.4B FY2020 FY2021 revenue 3.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-24-000015 FY2021 net income -329.7M · NetIncomeLoss, 0001232524-24-000015 3.1B FY2021 FY2022 revenue 3.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-25-000011 FY2022 net income -224.1M · NetIncomeLoss, 0001232524-25-000011 3.7B FY2022 FY2023 revenue 3.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-26-000013 FY2023 net income 414.8M · NetIncomeLoss, 0001232524-26-000013 3.8B FY2023 FY2024 revenue 4.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-26-000013 FY2024 net income 560.1M · NetIncomeLoss, 0001232524-26-000013 4.1B FY2024 FY2025 revenue 4.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001232524-26-000013 FY2025 net income -356.1M · NetIncomeLoss, 0001232524-26-000013 4.3B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

From the same starting line, FY2016 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2016. What happened, from the 10-Ks. Not a forecast.

FY2016 = 100
100 200 Revenue: $1.5B in FY2016, $4.3B in FY2025 REVENUE $4.3B · 2.9x Free cash flow: $582.7M in FY2016, $1.3B in FY2025 FREE CASH FLOW $1.3B · 2.2x FY2016 = 100FY2021FY2025
Revenue 2.9x $1.5B to $4.3B
Free cash flow 2.2x $582.7M to $1.3B

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +10.1% a year FY2015 $27.07 to FY2025 $70.82, 10 years
Free cash flow per share +10.5% a year FY2015 $7.87 to FY2025 $21.27, 10 years
100 150 200 250 Book value / share: $27.07 in FY2015, $70.82 in FY2025 BOOK VALUE / SHARE $70.82 · 2.6x FCF / share: $7.87 in FY2015, $21.27 in FY2025 FCF / SHARE $21.27 · 2.7x FY2015 = 100FY2020FY2025

Each line is set to 100 in FY2015, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$5.84$70.82$21.27
Dec 31, 2024 $8.65$62.02$20.57
Dec 31, 2023 $6.10$51.86$14.82
Dec 31, 2022 -$3.58$49.34$19.87
Dec 31, 2021 -$5.52$66.43$12.58
Dec 31, 2020 $4.22$64.75$15.65
Dec 31, 2019 $9.09$54.06$12.79
Dec 31, 2018 $7.30$45.04$12.72
Dec 31, 2017 $7.96$44.25$10.83
Dec 31, 2016 $6.41$30.34$9.42
Dec 31, 2015 $5.23$27.07$7.87

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $4.2B
  • − All liabilities (total assets less equity) $7.3B
  • = Net current asset value -$3.2B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $4.3B
  • − Goodwill $1.8B
  • − Other intangible assets $4.4B
  • = Tangible book value -$1.9B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result. This company does not tag total liabilities, so total assets less equity is used (it includes any non-controlling interest).

JAZZ against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+4.9%116th of 155 · median +10.5%
Net margin
-4.1%15.3%
4.4%82nd of 154 · median 6.8%
Return on equity
-5.2%18.5%
4.9%90th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
34.4%7th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.3389th of 108 · median 0.69
JAZZ and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
JAZZ Jazz Pharmaceuticals plc$4.7B +4.9%-4.4%4.9%34.4%1.33
ELAN Elanco Animal Health Inc$5.1B +6.2%56.2%-2.9%-2.2%7.9%0.52
DXCM Dexcom$5.1B +15.6%63.4%19.4%39.1%21.5%-
ALNY Alnylam Pharmaceuticals, Inc.$5.0B +65.2%77.4%52.8%73.5%16.1%-
IDXX Idexx Laboratories$4.7B +10.4%62.7%25.4%63.2%28.0%0.20
ILMN Illumina, Inc.$4.5B -0.7%67.9%19.7%28.5%23.3%0.57
All 162 companies in the group

Where the $4.3B of revenue came from

by region, year to Dec 31, 2025

  • United States - federal $3.8B · 90%
  • Europe $341.1M · 8%
  • All other $94.9M · 2%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -8.2% FY2020: 6.5% net income ÷ equity
Net margin -8.3% FY2020: 10.1% profit per $ of sales: -356.1M ÷ 4.3B
Asset turnover 0.37× FY2020: 0.36× sales per $ of assets: 4.3B ÷ 11.7B
Leverage 2.70× FY2020: 1.79× assets per $ of equity: 11.7B ÷ 4.3B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    4.4% vs 6.8%
  • Return on equity below 15%
    4.9%
  • A profit in 7 of 10 years
Net margin, FY2016 to FY2025: 26.7% to -8.3%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -1.7× interest expense
  • Debt larger than equity
    Debt / equity 1.33 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 1.82
  • Net debt under 3 years of free cash flow
    $3.5B net debt, 2.2 years
Debt / equity at each year end, FY2016 to FY2025: 1.08 to 1.24

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $1.3B last year
  • Share count up over 5 years
    +7.9%
Free cash flow, FY2016 to FY2025: 582.7M to 1.3B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$2.6B of principal due, schedule of Sep 30, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

JAZZ's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue4.3B
FY2016: 1.5BFY2017: 1.6BFY2018: 1.9BFY2019: 2.2BFY2020: 2.4BFY2021: 3.1BFY2022: 3.7BFY2023: 3.8BFY2024: 4.1BFY2025: 4.3B FY2017FY2019FY2021FY2023FY2025
Net income-356.1M
FY2016: 396.8MFY2017: 487.8MFY2018: 447.1MFY2019: 523.4MFY2020: 238.6MFY2021: -329.7MFY2022: -224.1MFY2023: 414.8MFY2024: 560.1MFY2025: -356.1M FY2017FY2019FY2021FY2023FY2025
Free cash flow1.3B
FY2016: 582.7MFY2017: 664.1MFY2018: 778.5MFY2019: 736.3MFY2020: 884.6MFY2021: 750.9MFY2022: 1.2BFY2023: 1.1BFY2024: 1.4BFY2025: 1.3B FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay1.0B
FY2016: 483.9MFY2017: 557.2MFY2018: 676.1MFY2019: 625.7MFY2020: 763.6MFY2021: 561.9MFY2022: 1.0BFY2023: 841.2MFY2024: 1.1BFY2025: 1.0B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-5.84
FY2016: 6.41FY2017: 7.96FY2018: 7.30FY2019: 9.09FY2020: 4.22FY2021: -5.52FY2022: -3.58FY2023: 6.10FY2024: 8.65FY2025: -5.84 FY2017FY2019FY2021FY2023FY2025
Diluted shares61.0M
FY2016: 61.9MFY2017: 61.3MFY2018: 61.2MFY2019: 57.5MFY2020: 56.5MFY2021: 59.7MFY2022: 62.5MFY2023: 72.1MFY2024: 66.0MFY2025: 61.0M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Product sales, net 4.0B94.2% +5.3%
Xywav 1.7B38.8% +12.5%
Epidiolex/Epidyolex 1.1B24.8% +8.9%
Rylaze/Enrylaze 402.9M9.4% -1.9%
Zepzelca 307.3M7.2% -4.1%
Royalties and contract revenues 245.7M5.8% -0.8%
High-sodium oxybate AG royalty revenue 211.7M5.0% -2.7%
Defitelio/defibrotide 199.4M4.7% -7.9%
Vyxeos 146.7M3.4% -9.8%
Xyrem 146.0M3.4% -37.5%
Modeyso 48.0M1.1% -
Other royalty and contract revenues 34.0M0.8% +12.6%
Ziihera 24.8M0.6% +2261%
Sativex 16.3M0.4% -13.8%
Other 14.2M0.3% +23.5%

10-K 0001232524-26-000013, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States - federal 3.8B89.8% +4.7%
Europe 341.1M8.0% +9.1%
All other 94.9M2.2% -1.3%

10-K 0001232524-26-000013, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1.5B1.6B1.9B2.2B2.4B3.1B3.7B3.8B4.1B4.3B
R&D162.3M198.4M226.6M299.7M335.4M505.7M590.5M849.7M884.0M782.7M
SG&A502.9M544.2M683.5M736.9M854.2M1.5B1.4B1.3B1.4B1.8B
Operating income591.7M528.8M614.8M532.4M378.1M170.3M-65.5M578.6M716.6M-430.2M
Interest expense27.5M37.8M56.7M62.5M87.6M89.9M32.8M32.8M314.8M248.6M
Pretax income532.4M441.1M529.5M454.3M275.1M-112.8M-372.8M297.9M470.4M-627.9M
Income tax135.2M-47.7M80.2M-73.2M33.5M216.1M-158.6M-119.9M-91.4M-272.4M
Net income396.8M487.8M447.1M523.4M238.6M-329.7M-224.1M414.8M560.1M-356.1M
EPS (diluted)6.417.967.309.094.22-5.52-3.586.108.65-5.84
Diluted shares61.9M61.3M61.2M57.5M56.5M59.7M62.5M72.1M66.0M61.0M
Depreciation & amortization11.8M13.1M15.2M15.3M18.7M26.7M30.3M30.4M32.8M41.6M
EBITDA603.5M541.9M630.0M547.7M396.8M197.0M-35.2M609.0M749.4M-388.6M
Operating margin39.8%32.7%32.5%24.6%16.0%5.5%-1.8%15.1%17.6%-10.1%
Net margin26.7%30.1%23.6%24.2%10.1%-10.7%-6.1%10.8%13.8%-8.3%
Revenue growth+12.3%+8.8%+16.8%+14.3%+9.3%+30.9%+18.3%+4.8%+6.1%+4.9%
EPS growth+22.6%+24.2%-8.3%+24.5%-53.6%to a loss--+41.8%to a loss

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow592.4M693.1M798.9M776.4M899.6M778.5M1.3B1.1B1.4B1.4B
Capital spending9.7M28.9M20.4M40.1M15.0M27.6M29.0M24.0M38.1M58.8M
Free cash flow582.7M664.1M778.5M736.3M884.6M750.9M1.2B1.1B1.4B1.3B
Stock-based pay (added back)98.8M106.9M102.4M110.6M121.0M189.0M222.0M226.8M248.0M291.1M
Free cash flow after stock pay483.9M557.2M676.1M625.7M763.6M561.9M1.0B841.2M1.1B1.0B
Buybacks278.3M98.8M523.7M301.4M146.5M054K269.8M311.4M125.0M
Acquisitions1.5B00006.2B00--
Debt raised994.6M559.4M0001.5B00--
Investing cash flow-1.8B-268.9M-394.5M-155.3M-1.0B-5.2B-446.2M-163.1M-508.2M-1.5B
Financing cash flow541.0M-409.1M-479.1M-293.7M528.1M4.0B-529.5M-305.3M20.5M-873.4M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)98.8M106.9M102.4M110.6M121.0M189.0M222.0M226.8M248.0M291.1M
Stock-based pay / revenue6.6%6.6%5.4%5.1%5.1%6.1%6.1%5.9%6.1%6.8%
Operating lease cost---23.1M21.8M23.9M19.7M19.4M22.2M23.9M
Operating lease cash paid---17.1M21.7M24.8M20.5M20.6M33.6M20.7M
Finance lease principal paid---00324K429K377K442K370K
Right-of-use assets--0139.4M129.2M86.6M73.3M65.3M53.6M58.9M
Operating lease liabilities--0164.0M154.5M102.6M87.4M78.2M53.3M65.2M
Finance lease liabilities-----6.7M5.6M5.5M5.0M3.9M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JAZZ/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.